\n 80.5%% of retail investor accounts lose money when trading CFDs <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n\n \n
Why Invest in AstraZeneca?<\/h2>\n AstraZeneca stock has performed extremely well in the financial markets since the 1999 merger of Zeneca Group and Astra AB. At the time of writing this article in May 2020, the company is at high-time highs.<\/p>\n
Will the stock continue its upward trajectory? Below we have listed some of the many reasons that analysts believe it will.<\/p>\n
Coronavirus has made Pharma Companies a Buy<\/h3>\n Make no mistake about it, the impact of the coronavirus pandemic on the global financial markets could be catastrophic. Whether it\u2019s airlines, hospitality, real estate, construction, or retail, heaps of industries likely have tough times ahead of them.<\/p>\n
With that said, the pandemic will potentially have the opposite effect on large-scale pharmaceutical companies like AstraZeneca. At the forefront of this is the firm\u2019s research and development of COVID-19 related treatments.\u00a0 CEO Pascal Soriot recently told the BBC that the company is aiming for a Coronavirus vaccine by the end of 2020.<\/p>\n
While there is no guarantee that AstraZeneca will realize this ambitious objective, the key point is that there is no reason to believe that the wider pharma space will be economically impacted by the pandemic. If anything, it\u2019s possible that the opposite will happen.<\/p>\n
37% Stock Price Growth and in All-Time High Territory<\/h3>\n AstraZeneca stocks have been on fire for some time now. As of May 2020, the company\u2019s shares are up 37% from the prior 12 months. When you factor in the wider economic impact of the COVID-19 pandemic, this once again highlights that pharma stocks are highly sought-after in troubling times.<\/p>\n
The Dow Jones index, for example, has dropped 17% in the same period.\u00a0Even more pertinently, Astazenan stocks are currently in all-time high territory. This highlights that investor sentiment is extremely bullish on the firm.<\/p>\n
Huge Portfolio of Approved Treatments<\/h3>\n AstraZeneca was able to obtain regulatory approval on over 23 treatments in 2018. This includes everything from kidney and cardiovascular disorders to cancer. The company is also at the final stages of several other new products that it expects to gain approval for within the next 1-2 years. This is one of the key reasons that the company has forecast double-digit growth in 2021.<\/p>\n
About AstraZeneca Stock<\/h2>\nCompany and Stock history<\/h3>\n AstraZeneca as a PLC was officially launched in 1999 on the back of a large-scale merger between the UK\u2019s Zeneca Group and Astra AB of Sweden. The firm\u2019s key revenue stream centres on the research, development, and distribution of pharmaceutical and biopharmaceutical products. This includes a range of health care segments, including but not limited to diabetes, cancer, cardiovascular, aesthetic, and infectious diseases.<\/span><\/p>\n
AstraZeneca is listed on the London Stock Exchange under the ticker symbol AZN, and it is one of the largest constituents of the FTSE 100 index. As of May 2020, the firm has a total market capitalization of \u00a3115 billion. Its operations span several continents, which includes a workforce in excess of 61,000 employees.<\/span><\/p>\nIn terms of the company\u2019s stock price, AstraZeneca shares were priced at 2,721p in 1999. Fast forward to May 2020 and they are at an all-time high 9,056p. This represents a very juicy increase of just over 200% which once again highlights that AstraZeneca has been a strong long-term hold for investors. To complement this, AstraZeneca has a long-standing history of paying healthy dividends. This was exceeding a yield of 4% in 2018, although since then this has been reduced to the 2%-3.5% range.<\/p>\n
Should I Buy AstraZeneca Stock?<\/h2>\n At current prices, AstraZeneca is trading at just over 5 times its forecast sales for 2020. Although some would argue that this is somewhat expensive, investors seem content to pay a premium for the stock. This bullish sentiment has been reflected in the company\u2019s share price, with AstraZeneca seeing year-on-year gains of 37% in 2020. <\/span>This is on top of a dividend yield of between 2% and 3.5%, so income seekers have also been catered for. <\/span><\/p>\nThere is much excitement about the firm moving into the next couple of years. Not only is AstraZeneca confident in its development of a COVID-19 vaccine, but it has also received heaps of regulatory approvals in other health segments. This is why the company is projecting growth of well over 13% in 2021. <\/span>All in all, pharma companies are often sought after in times of economic uncertainties, which some argue will only push AstraZeneca to new heights. <\/span><\/p>\nFAQ<\/h2>\n <\/time><\/time>